361 related articles for article (PubMed ID: 22941649)
1. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
McNeil EM; Melton DW
Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
[TBL] [Abstract][Full Text] [Related]
3. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
Kirschner K; Melton DW
Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
[TBL] [Abstract][Full Text] [Related]
4. Function and Interactions of ERCC1-XPF in DNA Damage Response.
Faridounnia M; Folkers GE; Boelens R
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563071
[TBL] [Abstract][Full Text] [Related]
5. The ERCC1 and ERCC4 (XPF) genes and gene products.
Manandhar M; Boulware KS; Wood RD
Gene; 2015 Sep; 569(2):153-61. PubMed ID: 26074087
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
[TBL] [Abstract][Full Text] [Related]
7. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
Gentile F; Barakat KH; Tuszynski JA
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
[TBL] [Abstract][Full Text] [Related]
8. Physiological consequences of defects in ERCC1-XPF DNA repair endonuclease.
Gregg SQ; Robinson AR; Niedernhofer LJ
DNA Repair (Amst); 2011 Jul; 10(7):781-91. PubMed ID: 21612988
[TBL] [Abstract][Full Text] [Related]
9. Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?
Bergstralh DT; Sekelsky J
Trends Genet; 2008 Feb; 24(2):70-6. PubMed ID: 18192062
[TBL] [Abstract][Full Text] [Related]
10. Multiple DNA binding domains mediate the function of the ERCC1-XPF protein in nucleotide excision repair.
Su Y; Orelli B; Madireddy A; Niedernhofer LJ; Schärer OD
J Biol Chem; 2012 Jun; 287(26):21846-55. PubMed ID: 22547097
[TBL] [Abstract][Full Text] [Related]
11. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
[TBL] [Abstract][Full Text] [Related]
12. The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways.
Orelli B; McClendon TB; Tsodikov OV; Ellenberger T; Niedernhofer LJ; Schärer OD
J Biol Chem; 2010 Feb; 285(6):3705-3712. PubMed ID: 19940136
[TBL] [Abstract][Full Text] [Related]
13. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
[TBL] [Abstract][Full Text] [Related]
14. Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52.
Motycka TA; Bessho T; Post SM; Sung P; Tomkinson AE
J Biol Chem; 2004 Apr; 279(14):13634-9. PubMed ID: 14734547
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1.
Tsodikov OV; Enzlin JH; Schärer OD; Ellenberger T
Proc Natl Acad Sci U S A; 2005 Aug; 102(32):11236-41. PubMed ID: 16076955
[TBL] [Abstract][Full Text] [Related]
16. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
[TBL] [Abstract][Full Text] [Related]
17. Cryo-EM structures of the XPF-ERCC1 endonuclease reveal how DNA-junction engagement disrupts an auto-inhibited conformation.
Jones M; Beuron F; Borg A; Nans A; Earl CP; Briggs DC; Snijders AP; Bowles M; Morris EP; Linch M; McDonald NQ
Nat Commun; 2020 Feb; 11(1):1120. PubMed ID: 32111838
[TBL] [Abstract][Full Text] [Related]
18. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks.
Niedernhofer LJ; Odijk H; Budzowska M; van Drunen E; Maas A; Theil AF; de Wit J; Jaspers NG; Beverloo HB; Hoeijmakers JH; Kanaar R
Mol Cell Biol; 2004 Jul; 24(13):5776-87. PubMed ID: 15199134
[TBL] [Abstract][Full Text] [Related]
19. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
[TBL] [Abstract][Full Text] [Related]
20. Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.
Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Weilbeer C; Mani RS; Barakat KH; Tuszynski JA; Weinfeld M; West FG
J Med Chem; 2019 Sep; 62(17):7684-7696. PubMed ID: 31369707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
